| Abstract: |
Prostate cancer is the second most common malignancy among men. In addition to clinical information, benign findings and pitfalls in PET/CT reading using various radiotracers, and teaching cases, this chapter reviews evidence-based recommendations regarding PET/CT examination in prostate cancer and compares them with statements in major clinical guidelines. The major guidelines do not support utilization of fludeoxyglucose (FDG) PET/CT for the evaluation of prostate cancer. However, according to evidence-based data, FDG PET/CT provides prognostic value and may be beneficial for therapy monitoring in castrate-resistant metastatic disease with poorly differentiated tumor. PET radiotracers, such as 11C-and 18F-choline and 11C-acetate, seem to be promising in staging of high-risk prostate cancer. They showed a good performance in the therapy monitoring of patients with metastatic prostate cancer. On the other hand, 68Ga-PSMA PET/CT is more sensitive than CT or MRI for the detection of metastatic disease in patients with intermediate-to high-risk prostate cancer, even at low serum prostate-specific antigen values. As another imaging method, 18F-NaF PET/CT is superior to conventional bone scintigraphy and provides excellent performance in the assessment of bone metastasis. © 2018 Elsevier Inc. |
